Katherine  Stueland net worth and biography

Katherine Stueland Biography and Net Worth

CEO of GeneDx

Katherine Stueland has dedicated her career to transforming healthcare through leadership at patient-centric businesses.  Her career has spanned supporting the FDA approval of several rare disease therapeutics, the first protease inhibitor for HIV/AIDS and the first cancer immunotherapy, all of which were made possible by the powerful voices of patient advocates. Over the past decade, Katherine has been a central figure in moving healthcare toward widespread use of genomic information to improve the accuracy and effectiveness of the diagnosis of rare disease and cancer.  
 
In June 2021, Katherine became the President and CEO of GeneDx (Nasdaq: WGS), a company that emerged from the National Institutes of Health and today is at the forefront of transforming healthcare through genomic insights with a mission to end the diagnostic odyssey. GeneDx delivers personalized and actionable health insights to inform diagnosis, direct treatment and drug discovery. Katherine led the company through a massive company transformation, focusing the business on its industry-leading exome and genome testing and interpretation products, fueled by one of the world’s largest, rare disease data sets. Under her leadership, GeneDx has nearly tripled the number of patients it’s been able to sequence, completing nearly 750,000 exomes and genomes while at the same time leading the company toward profitability and a market cap of more than $1 billion.  

Katherine’s career is rooted in bringing transformational technologies to market and crafting strategies to evolve a new standard of care to keep people healthier and living longer lives. Prior to GeneDx, Katherine was the Chief Commercial Officer of Invitae , a medical genetics company where she established the corporate brand as the company evolved from a private to a public entity. 
 
In 2023, Katherine was recognized as one of the most influential people in biotech by Fierce Pharma and was a runner up for the most influential leaders by Modern Healthcare.  She serves on the JED Foundation Leadership Council, a nonprofit organization that works to prevent suicide and protect the emotional health of young adults and teens as part of her lifetime commitment to help improve mental health and fitness. Katherine is also passionate about mentoring women on effective leadership, creating human-centric business strategies, and generating career opportunities for emerging leaders. Katherine graduated from Miami University in Oxford, Ohio, in 1997 with a bachelor’s degree in Science and English Literature. 

What is Katherine Stueland's net worth?

The estimated net worth of Katherine Stueland is at least $6.16 million as of June 16th, 2026. Ms. Stueland owns 104,372 shares of GeneDx stock worth more than $6,158,992 as of June 19th. This net worth estimate does not reflect any other assets that Ms. Stueland may own. Learn More about Katherine Stueland's net worth.

How do I contact Katherine Stueland?

The corporate mailing address for Ms. Stueland and other GeneDx executives is 333 Ludlow Street North Tower 8th Floor, Stamford CT, 06902. GeneDx can also be reached via phone at 800-298-6470 and via email at [email protected]. Learn More on Katherine Stueland's contact information.

Has Katherine Stueland been buying or selling shares of GeneDx?

In the last ninety days, Katherine Stueland has sold $975,407.48 in GeneDx stock. Most recently, Katherine Stueland sold 10,501 shares of the business's stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $60.77, for a transaction totalling $638,145.77. Following the completion of the sale, the chief executive officer now directly owns 104,372 shares of the company's stock, valued at $6,342,686.44. Learn More on Katherine Stueland's trading history.

Who are GeneDx's active insiders?

GeneDx's insider roster includes Shawn Assad (CAO), Daniel Clark (General Counsel), James Coffin (COO), Bryan Dechairo (COO), Kevin Feeley (CFO), Keith Meister (Director), Richard Pfenniger, Jr. (Director), Richard Pfenniger, Jr. (Director), Anthony Prentice (Insider), Isaac Ro (CFO), Joshua Ruch (Director), Jason Ryan (Chairman of the Board), Eric Schadt (CEO), and Katherine Stueland (CEO). Learn More on GeneDx's active insiders.

Are insiders buying or selling shares of GeneDx?

In the last year, GeneDx insiders bought shares 13 times. They purchased a total of 2,425,941 shares worth more than $106,603,951.31. In the last year, insiders at the sold shares 34 times. They sold a total of 770,540 shares worth more than $88,161,486.81. The most recent insider tranaction occured on June, 16th when CFO Kevin Feeley sold 3,729 shares worth more than $226,611.33. Insiders at GeneDx own 25.2% of the company. Learn More about insider trades at GeneDx.

Information on this page was last updated on 6/16/2026.

Katherine Stueland Insider Trading History at GeneDx

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/16/2026Sell10,501$60.77$638,145.77104,372View SEC Filing Icon  
6/9/2026Sell3,639$53.77$195,669.0396,123View SEC Filing Icon  
4/29/2026Sell2,172$65.19$141,592.6893,216View SEC Filing Icon  
3/26/2026Sell46,933$63.17$2,964,757.6191,514View SEC Filing Icon  
3/16/2026Sell17,179$76.80$1,319,347.2058,447View SEC Filing Icon  
3/4/2026Sell25,459$78.61$2,001,331.9938,683View SEC Filing Icon  
1/29/2026Sell1,653$94.00$155,382.0016,458View SEC Filing Icon  
12/16/2025Sell10,857$143.89$1,562,213.7314,237View SEC Filing Icon  
12/9/2025Sell3,639$159.28$579,619.926,344View SEC Filing Icon  
10/29/2025Sell2,158$136.54$294,653.323,436View SEC Filing Icon  
9/16/2025Sell10,501$121.47$1,275,556.4714,578View SEC Filing Icon  
7/29/2025Sell2,154$105.31$226,837.743,440View SEC Filing Icon  
7/9/2025Sell3,220$93.00$299,460.001,720View SEC Filing Icon  
7/1/2025Sell9,657$90.94$878,207.584,940View SEC Filing Icon  
4/29/2025Sell2,154$113.09$243,595.863,440View SEC Filing Icon  
4/9/2025Sell46,594$89.62$4,175,754.281,720View SEC Filing Icon  
3/26/2025Sell46,551$95.62$4,451,206.6248,314View SEC Filing Icon  
3/17/2025Sell10,559$96.71$1,021,160.8914,865View SEC Filing Icon  
3/13/2025Sell1,078$89.44$96,416.326,674View SEC Filing Icon  
3/10/2025Sell2,731$94.73$258,707.637,752View SEC Filing Icon  
1/29/2025Sell1,657$78.48$130,041.363,937View SEC Filing Icon  
1/7/2025Sell51,420$94.48$4,858,161.601,720View SEC Filing Icon  
1/2/2025Sell18,006$78.18$1,407,709.0853,140View SEC Filing Icon  
12/16/2024Sell10,501$76.75$805,951.7571,146View SEC Filing Icon  
12/9/2024Sell3,661$76.37$279,590.5762,897View SEC Filing Icon  
11/18/2024Sell22,307$70.34$1,569,074.3860,011View SEC Filing Icon  
11/15/2024Sell23,108$70.48$1,628,651.8482,318View SEC Filing Icon  
10/29/2024Sell2,154$66.60$143,456.40105,426View SEC Filing Icon  
9/9/2024Sell3,639$33.33$121,287.8795,457View SEC Filing Icon  
7/29/2024Sell2,154$33.54$72,245.1692,550View SEC Filing Icon  
6/17/2024Sell7,683$28.31$217,505.7390,830View SEC Filing Icon  
6/10/2024Sell2,652$24.92$66,087.8479,763View SEC Filing Icon  
4/29/2024Sell6,325$11.04$69,828.0075,869View SEC Filing Icon  
3/18/2024Sell8,559$10.59$90,639.8166,698View SEC Filing Icon  
12/18/2023Sell11,734$2.16$25,345.4452,578View SEC Filing Icon  
9/18/2023Sell10,752$4.16$44,728.3242,689View SEC Filing Icon  
9/11/2023Sell2,675$4.62$12,358.5034,691View SEC Filing Icon  
6/20/2023Sell7,965$6.37$50,737.0530,819View SEC Filing Icon  
6/12/2023Sell2,674$6.49$17,354.2620,034View SEC Filing Icon  
5/16/2023Sell8,685$6.50$56,452.5016,162View SEC Filing Icon  
3/10/2023Sell2,807$11.88$33,347.169,350View SEC Filing Icon  
11/28/2022Buy5,611$17.82$99,988.025,611View SEC Filing Icon  
See Full Table

Katherine Stueland Buying and Selling Activity at GeneDx

This chart shows Katherine Stueland's buying and selling at GeneDx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

GeneDx Company Overview

GeneDx logo
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holdings Corp. was founded in 2017 and is headquartered in Stamford, Connecticut.
Read More

Today's Range

Now: $59.01
Low: $57.00
High: $59.43

50 Day Range

MA: $54.38
Low: $34.51
High: $69.83

2 Week Range

Now: $59.01
Low: $32.21
High: $170.87

Volume

658,675 shs

Average Volume

1,176,686 shs

Market Capitalization

$1.75 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.96